We are analyzing https://link.springer.com/article/10.1186/s12943-023-01733-x.

Title:
CD39/CD73/A2AR pathway and cancer immunotherapy | Molecular Cancer
Description:
Cancer development is closely associated with immunosuppressive tumor microenvironment (TME) that attenuates antitumor immune responses and promotes tumor cell immunologic escape. The sequential conversion of extracellular ATP into adenosine by two important cell-surface ectonucleosidases CD39 and CD73 play critical roles in reshaping an immunosuppressive TME. The accumulated extracellular adenosine mediates its regulatory functions by binding to one of four adenosine receptors (A1R, A2AR, A2BR and A3R). The A2AR elicits its profound immunosuppressive function via regulating cAMP signaling. The increasing evidence suggests that CD39, CD73 and A2AR could be used as novel therapeutic targets for manipulating the antitumor immunity. In recent years, monoclonal antibodies or small molecule inhibitors targeting the CD39/CD73/A2AR pathway have been investigated in clinical trials as single agents or in combination with anti-PD-1/PD-L1 therapies. In this review, we provide an updated summary about the pathophysiological function of the adenosinergic pathway in cancer development, metastasis and drug resistance. The targeting of one or more components of the adenosinergic pathway for cancer therapy and circumvention of immunotherapy resistance are also discussed. Emerging biomarkers that may be used to guide the selection of CD39/CD73/A2AR-targeting treatment strategies for individual cancer patients is also deliberated.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

pubmed, cancer, adenosine, article, cells, google, scholar, cas, immune, cell, central, pathway, tumor, aar, receptor, antitumor, expression, tme, immunotherapy, targeting, immunosuppressive, combination, carcinoma, signaling, cdcdaar, atp, extracellular, inhibitors, clinical, patients, tumors, shown, inhibition, activation, therapy, response, checkpoint, responses, immunol, including, regulatory, immunity, blockade, production, activity, microenvironment, solid, lung, mab, inhibitor,

Topics {✒️}

anti-cd39/tgf-β bispecific mab g-protein-coupled stimulatory pathways neutralize autocrine/paracrine tgf-β pd-1/pd-l1 targeted therapy hypoxia-a2-adenosinergic tumor biology cd39/cd73/a2ar-targeting treatment strategies anti-pd-1/anti-ctla4 antibodies article download pdf restore t-cell signaling cd39/cd73/a2ar pathways play inducing t-cell anergy anti-pd-1/pd-l1 therapies adenosine-a2a receptor pathway antigen-presenting cells cd39/cd73/adenosine/a2ar signaling cd39/cd73/adenosine-a2ar pathway targeting cd39/cd73/a2ar pathways activated cd39/cd73/a2ar signaling cd39/cd73/a2ar targeting mabs inhibit t-lymphocyte proliferation lipid nanoparticle-based system nk cell–based therapies anti-pd-1 monoclonal antibody crispr/cas9 mediated deletion cytotoxic t-cell infiltration liwu fu extensive search small-cell lung cancer redox-responsive nanovaccine combined iph5301-paclitaxel-trastuzumab combination group inflammasome-driven tumor immunity myeloid-derived suppressor cells small-molecule cd73 inhibitors adenosine/a2ar pathway resulted membrane-bound ectonucleotidases cd73 anti-pd-l1 mab hindering adenosine-mediated immunosuppression restore anti-tumor immunity eado receptor signalling tumor-mediated immune evasion anti-pd-l1 therapies high-affinity receptor expressed restores antitumor immunity de souza jb inflammatory bowel disease chemo-photodynamic therapy cd39/cd73/a2ar pathway cd39/cd73/a2ar pathway [128] cd39-cd73-a2ar pathway nk-cell maturation

Questions {❓}

Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?
Adenosine signaling: next checkpoint for gastric cancer immunotherapy?
Extracellular ATP and adenosine: the Yin and Yang in immune responses?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:CD39/CD73/A2AR pathway and cancer immunotherapy
         description:Cancer development is closely associated with immunosuppressive tumor microenvironment (TME) that attenuates antitumor immune responses and promotes tumor cell immunologic escape. The sequential conversion of extracellular ATP into adenosine by two important cell-surface ectonucleosidases CD39 and CD73 play critical roles in reshaping an immunosuppressive TME. The accumulated extracellular adenosine mediates its regulatory functions by binding to one of four adenosine receptors (A1R, A2AR, A2BR and A3R). The A2AR elicits its profound immunosuppressive function via regulating cAMP signaling. The increasing evidence suggests that CD39, CD73 and A2AR could be used as novel therapeutic targets for manipulating the antitumor immunity. In recent years, monoclonal antibodies or small molecule inhibitors targeting the CD39/CD73/A2AR pathway have been investigated in clinical trials as single agents or in combination with anti-PD-1/PD-L1 therapies. In this review, we provide an updated summary about the pathophysiological function of the adenosinergic pathway in cancer development, metastasis and drug resistance. The targeting of one or more components of the adenosinergic pathway for cancer therapy and circumvention of immunotherapy resistance are also discussed. Emerging biomarkers that may be used to guide the selection of CD39/CD73/A2AR-targeting treatment strategies for individual cancer patients is also deliberated.
         datePublished:2023-03-02T00:00:00Z
         dateModified:2023-03-02T00:00:00Z
         pageStart:1
         pageEnd:17
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12943-023-01733-x
         keywords:
            Immunosuppressive tumor microenvironment
            Cancer immunotherapy
            CD39
            CD73
            Adenosine receptor
            A2AR
            Cancer Research
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-023-01733-x/MediaObjects/12943_2023_1733_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-023-01733-x/MediaObjects/12943_2023_1733_Fig2_HTML.png
         isPartOf:
            name:Molecular Cancer
            issn:
               1476-4598
            volumeNumber:22
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Chenglai Xia
               affiliation:
                     name:Southern Medical University
                     address:
                        name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
                        type:PostalAddress
                     type:Organization
                     name:Southern Medical University
                     address:
                        name:School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Shuanghong Yin
               affiliation:
                     name:Southern Medical University
                     address:
                        name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
                        type:PostalAddress
                     type:Organization
                     name:Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center
                     address:
                        name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kenneth K. W. To
               affiliation:
                     name:The Chinese University of Hong Kong
                     address:
                        name:School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Liwu Fu
               affiliation:
                     name:Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center
                     address:
                        name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:CD39/CD73/A2AR pathway and cancer immunotherapy
      description:Cancer development is closely associated with immunosuppressive tumor microenvironment (TME) that attenuates antitumor immune responses and promotes tumor cell immunologic escape. The sequential conversion of extracellular ATP into adenosine by two important cell-surface ectonucleosidases CD39 and CD73 play critical roles in reshaping an immunosuppressive TME. The accumulated extracellular adenosine mediates its regulatory functions by binding to one of four adenosine receptors (A1R, A2AR, A2BR and A3R). The A2AR elicits its profound immunosuppressive function via regulating cAMP signaling. The increasing evidence suggests that CD39, CD73 and A2AR could be used as novel therapeutic targets for manipulating the antitumor immunity. In recent years, monoclonal antibodies or small molecule inhibitors targeting the CD39/CD73/A2AR pathway have been investigated in clinical trials as single agents or in combination with anti-PD-1/PD-L1 therapies. In this review, we provide an updated summary about the pathophysiological function of the adenosinergic pathway in cancer development, metastasis and drug resistance. The targeting of one or more components of the adenosinergic pathway for cancer therapy and circumvention of immunotherapy resistance are also discussed. Emerging biomarkers that may be used to guide the selection of CD39/CD73/A2AR-targeting treatment strategies for individual cancer patients is also deliberated.
      datePublished:2023-03-02T00:00:00Z
      dateModified:2023-03-02T00:00:00Z
      pageStart:1
      pageEnd:17
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12943-023-01733-x
      keywords:
         Immunosuppressive tumor microenvironment
         Cancer immunotherapy
         CD39
         CD73
         Adenosine receptor
         A2AR
         Cancer Research
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-023-01733-x/MediaObjects/12943_2023_1733_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-023-01733-x/MediaObjects/12943_2023_1733_Fig2_HTML.png
      isPartOf:
         name:Molecular Cancer
         issn:
            1476-4598
         volumeNumber:22
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Chenglai Xia
            affiliation:
                  name:Southern Medical University
                  address:
                     name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
                     type:PostalAddress
                  type:Organization
                  name:Southern Medical University
                  address:
                     name:School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Shuanghong Yin
            affiliation:
                  name:Southern Medical University
                  address:
                     name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
                     type:PostalAddress
                  type:Organization
                  name:Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center
                  address:
                     name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kenneth K. W. To
            affiliation:
                  name:The Chinese University of Hong Kong
                  address:
                     name:School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Liwu Fu
            affiliation:
                  name:Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center
                  address:
                     name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Molecular Cancer
      issn:
         1476-4598
      volumeNumber:22
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Southern Medical University
      address:
         name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
         type:PostalAddress
      name:Southern Medical University
      address:
         name:School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
         type:PostalAddress
      name:Southern Medical University
      address:
         name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
         type:PostalAddress
      name:Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center
      address:
         name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
         type:PostalAddress
      name:The Chinese University of Hong Kong
      address:
         name:School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China
         type:PostalAddress
      name:Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center
      address:
         name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Chenglai Xia
      affiliation:
            name:Southern Medical University
            address:
               name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
               type:PostalAddress
            type:Organization
            name:Southern Medical University
            address:
               name:School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Shuanghong Yin
      affiliation:
            name:Southern Medical University
            address:
               name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
               type:PostalAddress
            type:Organization
            name:Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center
            address:
               name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Kenneth K. W. To
      affiliation:
            name:The Chinese University of Hong Kong
            address:
               name:School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China
               type:PostalAddress
            type:Organization
      name:Liwu Fu
      affiliation:
            name:Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center
            address:
               name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
      name:School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
      name:Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China
      name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China
      name:School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China
      name:State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China

External Links {🔗}(500)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.28s.

LINK . SPRINGER . COM {}